Clinical Trial Update: Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update reports completion and results posting for selumetinib in patients with papillary thyroid carcinoma that did not respond to radi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillary Thyroid Carcinoma
• Thyroid Cancer

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Papillary Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-01-30